- Previous Close
6.85 - Open
7.15 - Bid 6.95 x --
- Ask 7.00 x --
- Day's Range
7.00 - 7.15 - 52 Week Range
5.85 - 16.92 - Volume
56 - Avg. Volume
0 - Market Cap (intraday)
680.914M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.45 - Earnings Date May 6, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
www.avadel.com188
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: AWK.F
View MorePerformance Overview: AWK.F
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AWK.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AWK.F
View MoreValuation Measures
Market Cap
680.91M
Enterprise Value
617.67M
Trailing P/E
--
Forward P/E
33.22
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.49
Price/Book (mrq)
10.44
Enterprise Value/Revenue
4.16
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-28.87%
Return on Assets (ttm)
-16.11%
Return on Equity (ttm)
-60.44%
Revenue (ttm)
169.12M
Net Income Avi to Common (ttm)
-48.83M
Diluted EPS (ttm)
-0.45
Balance Sheet and Cash Flow
Total Cash (mrq)
73.78M
Total Debt/Equity (mrq)
52.60%
Levered Free Cash Flow (ttm)
-30.37M